课题基金 / 基金详情

Core C: Medicinal Chemistry and DMPK

Core C: Medicinal Chemistry and DMPK
核心 C:药物化学和 DMPK
批准号:
10522807
负责人:
Thomas D Bannister
金额:
$1314.19万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-16 至 2025-04-30

项目摘要

项目成果

Thomas D Bannister的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Core C – Medicinal Chemistry and DMPK ABSTRACT The discovery of possible drug candidates requires effective collaboration of diverse teams of skilled scientists. Medicinal chemists fulfill a core problem solving role, generally leading efforts to overcome the myriad of obstacles sure to be encountered in any drug discovery campaign. A great many of these hurdles typically involve overcoming deficiencies in drug metabolism and pharmacokinetic (DMPK) properties. Core C of the Midwest AViDD Center centralizes medicinal chemistry and DMPK support functions, with a key role for computational chemistry in impacting hit-to-lead efforts. Core C is comprised of top researchers in their fields, located at 8 different research sites: Scripps-FL, U. Minnesota, Georgia State U, U. Illinois-Chicago, U. Mississippi, N.Y. Blood Center, U.C San Diego, and U.C. Berkeley. The effort seeks not to merely validate new targets and discover “probes” that are ill-suited for development but is focused on the delivery of agents with high translational potential. This philosophy derives in part from the extensive industrial experience of many key personnel in the core. Objectives include the identification and triage of validated hit series, their optimization to validated leads, and finally to the delivery of tractable orally bioavailable drug development candidates in multiple target areas for viruses with high pandemic potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers
Early development of small molecule neuroprotectants.
  • 批准号:
    9977268
  • 项目类别:
  • 资助金额:
    $76.71万
  • 财政年份:
    2018
  • 负责人:
    Thomas D Bannister
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: